BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2363941)

  • 1. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
    Enblad G; Glimelius B; Hagberg H; Lindemalm C
    Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
    Enblad G; Hagberg H; Glimelius B
    Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study.
    Enblad G; Hagberg H; Gustavsson A; Glimelius B
    Eur J Haematol; 1998 Mar; 60(3):166-71. PubMed ID: 9548415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
    Mirza MR; Brincker H
    Acta Oncol; 1991; 30(1):17-21. PubMed ID: 2009179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
    Nowrousian MR; Anders CH; Niederle N; Nagel-Hiemke M; Moritz T; Seeber S; Schmidt CG
    Ann Oncol; 1991 Jan; 2 Suppl 1():25-30. PubMed ID: 1710486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
    Hagemeister FB; Tannir N; McLaughlin P; Salvador P; Riggs S; Velasquez WS; Cabanillas F
    J Clin Oncol; 1987 Apr; 5(4):556-61. PubMed ID: 3559649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
    Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
    Sandlund JT; Pui CH; Mahmoud H; Zhou Y; Lowe E; Kaste S; Kun LE; Krasin MJ; Onciu M; Behm FG; Ribeiro RC; Razzouk BI; Howard SC; Metzger ML; Hale GA; Rencher R; Graham K; Hudson MM
    Ann Oncol; 2011 Feb; 22(2):468-71. PubMed ID: 20624787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma Groups.
    Child JA; Simmons AV; Barnard DL; Parapia L; Morgan M; Grace RJ; Fletcher J; Parker D; Norfolk DR; Stone J
    Hematol Oncol; 1991; 9(4-5):235-44. PubMed ID: 1743626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
    Haim N; Ben-Shahar M; Epelbaum R
    Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.